Post-transplantation thrombotic microangiopathy (TMA), first described nearly 30 years ago, 1 remains an infrequent, but frustrating complication of SCT. The etiologies of this syndrome are thought to ...
Despite this advance in the treatment of TTP and resultant improvements in survival, significant gains in the understanding of TTP pathophysiology were not made until 2001 with the identification of ...
Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP). The ...
Pregnancy-onset thrombotic thrombocytopenic purpura (TTP) is a challenging condition with 3 distinct subtypes, which should be planned for in adults with a history of TTP. Adults with a history of ...
Transplantation-associated thrombotic microangiopathy (TA-TMA) continues to frustrate clinicians involved in the care of transplant recipients 22 years after it was first described. 1 Recent work has ...
Despite this advance in the treatment of TTP and resultant improvements in survival, significant gains in the understanding of TTP pathophysiology were not made until 2001 with the identification of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback